Merck has entered into a development agreement with US-based SFJ Pharmaceuticals Group (SFJ) to develop abituzumab in metastatic colorectal cancer. Merck executive board member and Merck healthcare CEO Belén Garijo said: “Our collaboration with SFJ […]
Novartis has secured a second approval for Kymriah (tisagenlecleucel) in the US for the treatment of adult patients with relapsed or refractory (r/r) large B-cell lymphoma who had more than two lines of systemic therapy. […]
Merck said that the US Food and Drug Administration (FDA) has accepted for review a supplemental Biologics License Application (sBLA) for its anti-PD-1 therapy Keytruda based on the results of the phase 3 KEYNOTE-189 trial. […]
Vivus has agreed to acquire all product rights for Pancreaze (pancrelipase) Delayed-Release Capsules in the US and Canada held by Janssen Pharmaceuticals, subject to certain closing conditions, including Hart-Scott-Rodino review. This is the first of […]
The UK National Institute for Health and Care Excellence (NICE) has recommended the use of Keytruda (pembrolizumab) within the Cancer Drugs Fund for the treatment of bladder cancer. Keytruda has been recommended as an option […]